> ViiV Healthcare teamed up with Radboud university medical center in the Netherlands to identify new early-stage HIV drug targets. Statement
> Amryt received clearance to enroll babies and infants in its phase 3 epidermolysis bullosa trial. The expansion follows an analysis of pharmacokinetic data on patients aged four years and older enrolled in the study. Release
> ReViral appointed Seth Hetherington as CMO. Hetherington joins ReViral from Genocea Biosciences. Statement
> Compugen detailed plans to lay off 35% of its staff and consolidate its R&D activities in Israel. The cuts, which largely affect R&D, are intended to ensure Compugen has the money to reach clinical proof-of-concept readouts. Release
> Quantum Genomics completed enrollment in a pharmacokinetic study of its modified release firibastat tablets. Statement
> Modus Therapeutics dosed the first cohort in a phase 1 trial of its sickle cell disease drug. Release